Phase 2RecruitingPriority 2 · High priorityNCT06698003
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Plain-language summary
This trial is testing Mogamulizumab for patients with adult T-cell leukemia/lymphoma (ATLL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 7 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Mogamulizumab (DRUG): Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
Mogamulizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details